We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Researchers Reverse Fragile X Syndrome Symptoms in Adult Mice
News

Researchers Reverse Fragile X Syndrome Symptoms in Adult Mice

Researchers Reverse Fragile X Syndrome Symptoms in Adult Mice
News

Researchers Reverse Fragile X Syndrome Symptoms in Adult Mice

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Researchers Reverse Fragile X Syndrome Symptoms in Adult Mice"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Neuroscientists at MIT’s Picower Institute for Learning and Memory report in the March 18 Proceedings of the National Academy of Sciences (PNAS) that they have reversed autism symptoms in adult mice with a single dose of an experimental drug.

The work from the laboratory of Nobel laureate Susumu Tonegawa, the Picower Professor in the Department of Biology and a principal investigator at the Picower Institute, points to potential targets for drugs that may one day improve autism symptoms such as hyperactivity, repetitive behaviors and seizures in humans by modifying molecular mechanisms underlying the disease.

“These findings suggest a possible novel therapeutic target for the treatment of Fragile X Syndrome (FXS) — the most common inherited form of autism and intellectual disability,” said Eric Klann, a professor of neural science at New York University.

Using genetically modified mice that exhibit FXS symptoms, the researchers targeted neurons’ dendritic spines, small protrusions that receive signals from other neurons and are key to effective neuron-to-neuron communication within the brain. The researchers focused on spines in the temporal cortex, a part of the brain implicated in autism in humans.

Humans with FXS and autism, and the mouse model with FXS symptoms, have abnormally high densities of dendritic spines, leading to deficits in learning, cognition and behavior.

Tonegawa is scientific co-founder of Afraxis, a California-based company developing drugs that target p21-activated kinase or PAK, a key regulator of dendritic spines. Calling the inhibitor drug FRAX486, Tonegawa and colleagues demonstrated that inhibiting PAK with a single dose of FRAX496 reduced cellular and behavioral abnormalities in mice that model FXS.

Advertisement